Počet záznamů: 1
TRAIL (Apo2L) supresses growth of primary human leukemia and myelodysplasia progenitors
- 1.0191506 - UMG-J 20023088 RIV US eng J - Článek v odborném periodiku
Plášilová, M. - Živná, J. - Jelínek, J. - Neuwirtová, R. - Čermák, J. - Nečas, E. - Anděra, Ladislav - Stopka, T.
TRAIL (Apo2L) supresses growth of primary human leukemia and myelodysplasia progenitors.
Leukemia. Roč. 16, č. 1 (2002), s. 67-73. ISSN 0887-6924. E-ISSN 1476-5551
Grant CEP: GA AV ČR IAA5052001; GA ČR GA301/99/0350
Klíčová slova: TRAIL * leukemia * myelodysplasia
Kód oboru RIV: EB - Genetika a molekulární biologie
Impakt faktor: 4.693, rok: 2002
Recombinant His-TRAIL reduced the number of myeloid colonies from patients with myeloid leukemia and myelodysplstic syndromes. TRAIL did not affect normal human hematopoiesis but suppressed the growth of early primary leukemia progenitors.
Trvalý link: http://hdl.handle.net/11104/0087257
Počet záznamů: 1